| Enhanced plasminogen activator production of Syrian hamster embryo cells transformed by chemicals or the c-Ha-ras oncogene: type of plasminogen activators involved and their contribution to the transformed phenotype. | None |
| Replication blocks and sequence interaction specificities in the codon 12 region of the c-Ha-ras proto-oncogene induced by four carcinogens in vitro. | None |
| H-ras-mediated transformation stimulates vesicular emission of this histone-bound oncogene, which may interact with non-transformed cells. | None |
| Absence of mutations in codon 61 of the Ha-ras oncogene in epithelial cells transformed in vitro by 7,12-dimethylbenz(a)anthracene. | None |
| Fibronectin/laminin and their receptors in aberrant growth control in FR3T3 cells transformed by Ha-ras oncogene and epidermal growth factor gene. | None |
| Inhibition of gap-junctional intercellular communication between epithelial cells transformed by the activated H-ras-1 oncogene. | None |
| Two overlapping sequence motifs within the polyomavirus enhancer are independently the targets of stimulation by both the tumor promoter 12-O-tetradecanoylphorbol-13-acetate and the Ha-ras oncogene. | None |
| Loss of responsiveness of an AP1-related factor, PEBP1, to 12-O-tetradecanoylphorbol-13-acetate after transformation of NIH 3T3 cells by the Ha-ras oncogene. | None |
| the Arf-Egr-C/EBPbeta axis as an important determinant of cellular responses (senescence or transformation) to oncogenic Ras signaling | None |
| Reversible abrogation of IL-3 dependence by an inducible H-ras oncogene. | None |
| The cell cycle regulator ecdysoneless cooperates with H-Ras to promote oncogenic transformation of human mammary epithelial cells. | None |
| Point mutation in c-HA-ras oncogene in normal and abnormal cells. | None |
| Transformation of mouse mammary epithelial cells with the Ha-ras but not with the neu oncogene results in a gene dosage-dependent increase in transforming growth factor-alpha production. | None |
| Restriction fragment length polymorphism of the c-Ha-ras-1 proto-oncogene as a marker of genome alterations and susceptibility to the development of some human carcinomas. | None |
| MTH1 expression is required for effective transformation by oncogenic HRAS. | None |
| MTH1 expression is required for effective transformation of epithelial cells by oncogenic HRAS. | None |
| The data suggest a role for redox-dependent activation of wild-type KRAS through cysteine 118 in oncogenic HRAS-driven tumorigenesis. | None |
| Activation of Harvey ras oncogene by mutation at codon 12 is very rare in hemopoietic malignancies. | None |
| Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene. | None |
| Effects of triiodothyronine and tamoxifen on cell transformation induced by an activated c-Ha-ras oncogene. | None |